Viewpoint Capital Management LLC Has $1.54 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Viewpoint Capital Management LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,346 shares of the biopharmaceutical company’s stock after selling 2,400 shares during the period. Bristol-Myers Squibb comprises approximately 1.0% of Viewpoint Capital Management LLC’s investment portfolio, making the stock its 29th biggest holding. Viewpoint Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $1,537,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. McClarren Financial Advisors Inc. lifted its holdings in shares of Bristol-Myers Squibb by 532.7% during the fourth quarter. McClarren Financial Advisors Inc. now owns 1,879 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,582 shares in the last quarter. Institute for Wealth Management LLC. boosted its holdings in Bristol-Myers Squibb by 1.0% in the 4th quarter. Institute for Wealth Management LLC. now owns 30,056 shares of the biopharmaceutical company’s stock valued at $1,542,000 after purchasing an additional 296 shares during the period. Great Diamond Partners LLC increased its holdings in shares of Bristol-Myers Squibb by 9.2% during the fourth quarter. Great Diamond Partners LLC now owns 4,372 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 367 shares during the period. Global Assets Advisory LLC acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at approximately $5,161,000. Finally, Principal Securities Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $1,139,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Up 0.0 %

NYSE:BMY traded up $0.02 during mid-day trading on Friday, hitting $41.53. 20,542,742 shares of the company’s stock were exchanged, compared to its average volume of 15,934,426. Bristol-Myers Squibb has a fifty-two week low of $39.63 and a fifty-two week high of $65.38. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The firm has a market capitalization of $84.19 billion, a P/E ratio of -13.40, a PEG ratio of 14.20 and a beta of 0.43. The company has a 50 day simple moving average of $42.97 and a 200-day simple moving average of $48.16.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.05 earnings per share. As a group, research analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.78%. The ex-dividend date is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Societe Generale cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, BMO Capital Markets decreased their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.